JP2016528297A - 癌治療 - Google Patents
癌治療 Download PDFInfo
- Publication number
- JP2016528297A JP2016528297A JP2016536469A JP2016536469A JP2016528297A JP 2016528297 A JP2016528297 A JP 2016528297A JP 2016536469 A JP2016536469 A JP 2016536469A JP 2016536469 A JP2016536469 A JP 2016536469A JP 2016528297 A JP2016528297 A JP 2016528297A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- individual
- day
- aurka
- tsa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Description
Claims (25)
- 個体における癌を治療する方法であって、
有効量のトリコスタチンA(TSA)を個体に投与するステップ
を含む方法。 - 前記有効量は、個体におけるオーロラキナーゼA(AURKA)レベルを減少させるのに十分な量である、請求項1に記載の方法。
- 前記有効量は、個体におけるヒストンデアセチラーゼ(HDAC)活性を阻害し、オーロラキナーゼA(AURKA)レベルを減少させるのに十分な量である、請求項1に記載の方法。
- 前記有効量は約0.1mg/kg/日〜約10mg/kg/日である、請求項1に記載の方法。
- 前記有効量は約0.5mg/kg/日〜約5mg/kg/日である、請求項4に記載の方法。
- TSAが、個体に投与される唯一のAURKA阻害剤である、請求項5に記載の方法。
- 前記癌は、乳癌、胃癌、結腸癌、直腸癌、膀胱癌、膵癌、卵巣癌、前立腺癌、肺癌、血液癌、皮膚癌、及び悪性腫瘍からなる群から選択される少なくとも1種の癌を含む、請求項1に記載の方法。
- 投与が経口投与を含む、請求項1に記載の方法。
- 投与が静脈内投与を含む、請求項1に記載の方法。
- 個体における癌を治療する方法であって、
個体の身体から得られた腫瘍試料からオーロラキナーゼA(AURKA)発現のレベルを決定するステップと、
AURKA発現のレベルが過剰発現を示す場合に、有効量のトリコスタチンA(TSA)を個体に投与するステップと、
を含む方法。 - 前記有効量は、個体におけるオーロラキナーゼA(AURKA)レベルを減少させるのに十分な量である、請求項10に記載の方法。
- 前記有効量は、個体におけるヒストンデアセチラーゼ(HDAC)活性を阻害し、オーロラキナーゼA(AURKA)レベルを減少させるのに十分な量である、請求項10に記載の方法。
- 前記有効量は約0.1mg/kg/日〜約10mg/kg/日である、請求項10に記載の方法。
- 前記有効量は約0.5mg/kg/日〜約5mg/kg/日である、請求項13に記載の方法。
- TSAが、個体に投与される唯一のAURKA阻害剤である、請求項10に記載の方法。
- 前記癌は、乳癌、胃癌、結腸癌、直腸癌、膀胱癌、膵癌、卵巣癌、前立腺癌、肺癌、血液癌、皮膚癌、及び悪性腫瘍からなる群から選択される少なくとも1種の癌を含む、請求項10に記載の方法。
- 投与が経口投与を含む、請求項10に記載の方法。
- 投与が静脈内投与を含む、請求項10に記載の方法。
- 単独の又は主要なオーロラキナーゼA(AURKA)阻害剤としてのトリコスタチンA(TSA)と、
薬学的に許容可能な賦形剤又は担体と、
を含む医薬組成物。 - 経口投与用に製剤化されている、請求項19に記載の医薬組成物。
- 静脈内投与用に製剤化されている、請求項19に記載の医薬組成物。
- TSAを約1mg〜約500mgの量で含む、請求項19に記載の医薬組成物。
- TSAの量が、約0.1mg/kg/日〜約10mg/kg/日の用量に相当する、請求項22に記載の医薬組成物。
- TSAの量が、約0.5mg/kg/日〜約5mg/kg/日の用量に相当する、請求項23に記載の医薬組成物。
- TSAの量が、ヒストンデアセチラーゼ(HDAC)活性を阻害するのに有効である、請求項22に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361869039P | 2013-08-22 | 2013-08-22 | |
US61/869,039 | 2013-08-22 | ||
PCT/US2014/052209 WO2015027121A2 (en) | 2013-08-22 | 2014-08-22 | Cancer treatment |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019088425A Division JP2019167351A (ja) | 2013-08-22 | 2019-05-08 | 癌治療 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2016528297A true JP2016528297A (ja) | 2016-09-15 |
Family
ID=51794948
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016536469A Pending JP2016528297A (ja) | 2013-08-22 | 2014-08-22 | 癌治療 |
JP2019088425A Pending JP2019167351A (ja) | 2013-08-22 | 2019-05-08 | 癌治療 |
JP2021042699A Pending JP2021105005A (ja) | 2013-08-22 | 2021-03-16 | 癌治療 |
JP2023045826A Pending JP2023088996A (ja) | 2013-08-22 | 2023-03-22 | 癌治療 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019088425A Pending JP2019167351A (ja) | 2013-08-22 | 2019-05-08 | 癌治療 |
JP2021042699A Pending JP2021105005A (ja) | 2013-08-22 | 2021-03-16 | 癌治療 |
JP2023045826A Pending JP2023088996A (ja) | 2013-08-22 | 2023-03-22 | 癌治療 |
Country Status (12)
Country | Link |
---|---|
US (5) | US20160199323A1 (ja) |
EP (2) | EP3616754A1 (ja) |
JP (4) | JP2016528297A (ja) |
KR (5) | KR20160033779A (ja) |
CN (2) | CN105579101A (ja) |
AU (4) | AU2014308700A1 (ja) |
CA (1) | CA2921036A1 (ja) |
CL (1) | CL2016000397A1 (ja) |
EA (1) | EA037667B1 (ja) |
ES (1) | ES2755983T3 (ja) |
MX (1) | MX2016002307A (ja) |
WO (1) | WO2015027121A2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3616754A1 (en) * | 2013-08-22 | 2020-03-04 | Vanda Pharmaceuticals Inc. | Cancer treatment |
WO2021016203A1 (en) * | 2019-07-19 | 2021-01-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Pdlim2 as a biomarker for cancer and as an anti-cancer treatment target |
WO2023168201A1 (en) * | 2022-03-01 | 2023-09-07 | Vanda Pharmaceuticals Inc. | Trichostatin a (tsa) sensitivity in the treatment of tumors |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61176523A (ja) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
WO2002060430A1 (en) * | 2001-02-01 | 2002-08-08 | Cornell Research Foundation, Inc. | Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors |
WO2007067516A2 (en) * | 2005-12-06 | 2007-06-14 | Duke University | Multiple myeloma |
JP2007521259A (ja) * | 2003-06-27 | 2007-08-02 | アステラス製薬株式会社 | 軟部肉腫治療剤 |
JP2010516628A (ja) * | 2007-01-19 | 2010-05-20 | ザ ユニバーシティー オブ ブリティッシュ コロンビア | Hatアセチル化プロモーター及び免疫原性を促進する際のその組成物の使用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4218478A (en) * | 1979-01-05 | 1980-08-19 | Ruiko Oiwa | Trichostatin as an antiprotozoal agent |
CA1265431A (en) | 1985-01-08 | 1990-02-06 | Roderick John Macdonald | Electrode device for flare stack ignitor |
ES2555994T3 (es) | 2004-05-21 | 2016-01-12 | The Board Of Trustees Of The University Of Arkansas System | Uso de perfiles de expresión génica para predecir la supervivencia en un paciente con cáncer |
KR20090014393A (ko) | 2006-05-26 | 2009-02-10 | 셀진 코포레이션 | 조합 요법에서 면역조절 화합물을 사용하는 방법 및 조성물 |
US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
UA114421C2 (uk) * | 2012-06-04 | 2017-06-12 | Фармасайклікс Ллс | Кристалічна форма інгібітору тирозинкінази брутона |
CA2921037C (en) | 2013-08-22 | 2022-11-15 | Vanda Pharmaceuticals Inc. | Use of trichostatin a in the treatment of multiple myeloma |
EP3616754A1 (en) * | 2013-08-22 | 2020-03-04 | Vanda Pharmaceuticals Inc. | Cancer treatment |
-
2014
- 2014-08-22 EP EP19201777.0A patent/EP3616754A1/en active Pending
- 2014-08-22 EA EA201690445A patent/EA037667B1/ru unknown
- 2014-08-22 KR KR1020167004630A patent/KR20160033779A/ko active Application Filing
- 2014-08-22 JP JP2016536469A patent/JP2016528297A/ja active Pending
- 2014-08-22 AU AU2014308700A patent/AU2014308700A1/en not_active Abandoned
- 2014-08-22 KR KR1020177032020A patent/KR20170126018A/ko not_active IP Right Cessation
- 2014-08-22 CN CN201480046624.5A patent/CN105579101A/zh active Pending
- 2014-08-22 WO PCT/US2014/052209 patent/WO2015027121A2/en active Application Filing
- 2014-08-22 ES ES14789436T patent/ES2755983T3/es active Active
- 2014-08-22 KR KR1020217002758A patent/KR102315528B1/ko active IP Right Grant
- 2014-08-22 EP EP14789436.4A patent/EP3036007B1/en active Active
- 2014-08-22 CN CN201910836673.3A patent/CN110585184A/zh active Pending
- 2014-08-22 CA CA2921036A patent/CA2921036A1/en active Pending
- 2014-08-22 US US14/912,077 patent/US20160199323A1/en not_active Abandoned
- 2014-08-22 KR KR1020217033186A patent/KR20210127821A/ko not_active IP Right Cessation
- 2014-08-22 MX MX2016002307A patent/MX2016002307A/es unknown
- 2014-08-22 KR KR1020237010047A patent/KR20230047203A/ko not_active Application Discontinuation
-
2016
- 2016-02-22 CL CL2016000397A patent/CL2016000397A1/es unknown
-
2018
- 2018-05-15 US US15/980,644 patent/US10265282B2/en active Active
-
2019
- 2019-03-18 US US16/357,249 patent/US11078289B2/en active Active
- 2019-05-08 JP JP2019088425A patent/JP2019167351A/ja active Pending
- 2019-11-06 AU AU2019261718A patent/AU2019261718A1/en not_active Abandoned
-
2021
- 2021-03-16 JP JP2021042699A patent/JP2021105005A/ja active Pending
- 2021-06-28 US US17/359,986 patent/US11667718B2/en active Active
- 2021-11-03 AU AU2021261882A patent/AU2021261882B2/en active Active
-
2022
- 2022-03-30 AU AU2022202183A patent/AU2022202183B2/en active Active
-
2023
- 2023-03-22 JP JP2023045826A patent/JP2023088996A/ja active Pending
- 2023-04-25 US US18/306,601 patent/US20230257471A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61176523A (ja) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
WO2002060430A1 (en) * | 2001-02-01 | 2002-08-08 | Cornell Research Foundation, Inc. | Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors |
JP2007521259A (ja) * | 2003-06-27 | 2007-08-02 | アステラス製薬株式会社 | 軟部肉腫治療剤 |
WO2007067516A2 (en) * | 2005-12-06 | 2007-06-14 | Duke University | Multiple myeloma |
JP2010516628A (ja) * | 2007-01-19 | 2010-05-20 | ザ ユニバーシティー オブ ブリティッシュ コロンビア | Hatアセチル化プロモーター及び免疫原性を促進する際のその組成物の使用 |
Non-Patent Citations (3)
Title |
---|
DAVID M. VIGUSHIN ET AL.: "Trichostatin A Is a Histone Deacetylase Inhibitor with Potent Antitumor Activity against Breast Canc", CLINICAL CANCER RESEARCH, vol. 7, JPN6018014129, 16 January 2001 (2001-01-16), US, pages 971 - 976, ISSN: 0003946129 * |
JUNG-HYUN PARK ET AL.: "Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulationg Aurora-A", J MOL MED, vol. 86, JPN6018014131, 13 November 2007 (2007-11-13), pages 117 - 128, ISSN: 0003946131 * |
XU-HUI ZHANG ET AL.: "Aurora A,Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylas", CANCER BIOLOGY & THERAPY, vol. Vol.7, Issue 9, JPN6018014132, 2 June 2008 (2008-06-02), pages 1388 - 1397, ISSN: 0003946130 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2022202183B2 (en) | Cancer treatment | |
US11737993B2 (en) | Multiple myeloma treatment | |
JP2011518168A5 (ja) | ||
NZ716668B2 (en) | Cancer treatment | |
EP3125896A2 (en) | EXPRESSION LEVELS OF BCL-xL, BCL2, BCL-w, AND BAD AND CANCER THERAPIES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170817 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180424 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180724 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180925 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181024 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190108 |